companiesCompany
Biostar Pharmaceuticals
aka Chengdu Biostar
Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer.
Overview
Biostar Pharmaceuticals is a Chengdu biotechnology company built around genetically engineered epothilones. Its lead product utidelone was approved by the NMPA in March 2021 with capecitabine for recurrent or metastatic breast cancer after anthracyclines and taxanes; an oral formulation and trials in other tumours followed.
Headquarters
Chengdu, China, CN
Scorecard
All companies#231of 994 companies, score 11
- approved products +6
- targets +2
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Large private
Website